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Background. CD4+ T-lymphocyte monitoring is not routinely available in most resource-limited settings. We investigated pre-
dictors of time to CD4+ T-lymphocyte recovery in HIV-infected children on highly active antiretroviral (HAART) at Korle-Bu
TeachingHospital,Ghana.Methods.Timeto CD4+ T-lymphocyte recovery wasdeﬁned asachieving percent CD4+ T-lymphocytes
of 25%. We used Cox proportional hazard models for identifying signiﬁcant predictor variables. Results. Of the 233 children with
complete CD4+ T-lymphocyte data, the mean age at HAART initiation was 5.5 (SD = 3.1) years. The median recovery time
was 60 weeks (95% CL: 55–65). Evidence at baseline of severe suppression in CD4+ T-lymphocyte count adjusted for age, age
at HAART initiation, gender, and having parents alive were statistically signiﬁcant in predicting time to CD4+ T-lymphocyte
recovery. Conclusions. A targeted approach based on predictors of CD4+ T-lymphocyte recovery can be a viable and cost-eﬀective
way of monitoring HAART in HIV-infected children in resource-limited settings.
1.Introduction
HIV primarily targets CD4+ T-lymphocytes, and recent
studies have shown that during primary HIV infection, HIV
viral replication in CD4+ T-lymphocytes in gut-associated
lymphoid tissue (GALT) results in signiﬁcant CD4+ T-
lymphocyte depletion [1, 2]. Chronic HIV infection aﬀects
both quantitative and qualitative function of CD4+ T-
lymphocytes, and disease progression results from contin-
uous depletion of these cells with a concomitant increase
in risk for opportunistic infections, acquired immune deﬁ-
ciency syndrome (AIDS), and death [3–5]. Given the central
role of CD4+ T-lymphocytes in HIV pathogenesis, CD4+ T-
lymphocyte determination during the course of HIV disease
is one of the most reliable predictors of prognosis [6].
The therapeutic goal of highly active antiretroviral ther-
apy (HAART)istosuppressHIVviral replicationandrestore
immune function (i.e., CD4+ T-lymphocyte recovery). The
standard of care for monitoring treatment in HIV-infected
children is the routine laboratory monitoring of CD4+ T-
lymphocyte percentage or count and HIV viral load at least
every 3-4 months [6]. However, CD4+ T-lymphocyte and
viral load testing, for monitoring the eﬃcacy of HAART,
are not routinely available in most resource-limited settings
[7]. Though several low-cost and technically less complex
deviceshavebeendevelopedforCD4+T-lymphocytetesting,
there are still quite a number of centers in resource-limited
countries with no access to reliable CD4+ T-lymphocyte
testing [8, 9]. Furthermore, the cost of commercially avail-
able viral load testing is prohibitive (between $50 and $1002 AIDS Research and Treatment
per test), making it unaﬀordable and inaccessible to many
HIV treatment centers in resource-limited countries [10].
Several studies have demonstrated that the eﬃcacy of
HAART in HIV-infected children in resource-limited coun-
tries is comparable to that of children in resource-rich
countries [11–19]. Given the empirical obstacles of using
the standard of care for monitoring HAART therapy in
resource-limited countries and the need to develop clinical
practices that would reduce the overall cost of patient care,
we investigated factors aﬀecting treatment response among
HIV-positive children on HAART in a resource-limited
country. In particular, we examined the predictors of the
time to CD4+ T-lymphocyte recovery using retrospective
longitudinal data.
2.Methods
2.1. Study Cohort. This was a single center retrospective
study at the Pediatric HIV/AIDS Care program at Korle-Bu
Teaching Hospital in Accra, Ghana. The study population
consisted of all HIV-infected children on HAART, since
pediatric antiretroviral therapy became available in 2004. All
the patients included in the analysis were on their ﬁrst-line
regimen of nonnucleoside analog-based HAART consisting
of zidovudine (AZT) or stavudine (d4T) plus lamivudine
(3TC), plus either nevirapine (NVP) or efavirenz (EFV). We
analyzed longitudinal data extracted from medical records of
children on treatment with at least two CD4+ T-lymphocyte
determinations between June 2004 and December 2009. The
study was reviewed and approved by the Ethics and Protocol
Review Committees of University of Ghana Medical School
and Yale School of Medicine.
The main study outcome was time to CD4+ T-lym-
phocyte recovery, deﬁned as achieving and maintaining a
target CD4 percentage of 25% after initiation of HAART.
Because of well-known large natural decline and variation in
absolute CD4+ T-lymphocyte numbers in early childhood,
the percentage of CD4+ T-lymphocytes is preferentially used
in the management of pediatric HIV infection; the target is
to achieve at least 25% of CD4+ T-lymphocytes according to
age on treatment [20, 21].
The predictor variables included gender, age at start
of therapy, WHO clinical staging and WHO immune
classiﬁcation at baseline, mode of transmission, HIV and
living status of parents, TB diagnosis and treatment, being
a graduate of prevention of mother-to-child transmission
(PMTCT) program, and adherence to treatment regimen.
Since 2004, CD4+ T-lymphocyte counts and percentages
were done at least every 6months. CD4+ T-lymphocyte
count and percentage were quantiﬁed by a dual-platform
ﬂow cytometry technology using an FACSCount system
(Becton-Dickinson, Franklin Lakes, NJ) at the clinical
laboratory at Korle-Bu Teaching Hospital according to
manufacturer’s instructions. Samples were processed within
four hours. The laboratory is certiﬁed by the South African
Public Health Reference Laboratory and they participate
in an external quality assurance testing program by the
SouthAfrican PublicHealthReferenceLaboratory.Viralload
testing is not available routinely.
2.2. Statistical Analysis. Patient characteristics were summa-
rized with N and percentage. Kaplan-Meier approach was
used to describe the cumulative proportion of CD4+ T-
lymphocyte recovery as of particular time in the followup.
We used (1–Survival) to plot the trajectories of recovery
function over time. The median recovery time across the
categories of speciﬁc patient characteristics was evaluated
with the log-rank test. We used unadjusted Cox proportional
hazards (CPHs)modelstoevaluateindependentassociations
between each of the patient characteristics and the rate
of CD4+ T-lymphocyte recovery. The magnitudes of the
associations were summarized with hazard ratios (HRs) and
95% conﬁdence intervals (95% CI). Adjusted associations
were obtained from multivariate CPH. Signiﬁcance was
established with alpha of 0.05. All analyses were performed
with SAS 9.2 (Cary, NC).
3.Results
3.1. Characteristics of Study Population. Three hundred and
ﬁfty-one HIV-infected children were started on HAART
between 2004 and 2009 at the Pediatric HIV clinic at Korle-
Bu Teaching Hospital. During the study period, 233 of the
children on HAART had at least two CD4+ T-lymphocyte
counts and were included in our analysis. The followup time
ranged from 11 to349 weeks, with the median followup of
127weeks. There were two deaths; one died after meeting
the study’s primary outcome (i.e., CD4+ T-lymphocyte
recovery),andtheotherdiedafter54weekswithoutrecovery.
Both patients were included in the analysis. Table 1 illus-
trates the clinical and demographic characteristics of study
participants. About 96% of the children on HAART were a
year of age or older, with an almost equal male-to-female
ratio. The mean age at initiation of HAART was 5.5 (SD =
3.1) years, and the majority were started on HAART at an
advanced stage of their disease, corroborated by their WHO
clinical staging and immune classiﬁcation. About half of the
cohort had been diagnosed and treated for tuberculosis. Of
note is the small percentage (1.3%) of PMTCT graduates
who became infected with HIV and went on to HAART
treatment.
The baseline CD4+ T-lymphocyte count of children
between one and ﬁve years old was signiﬁcantly higher
than those older than six years (P<. 0001). The median
baselineCD4+T-lymphocytecountwas423(IQR:272–742),
531 (IQR: 305–774), and 174cells/mm3 (IQR: 35–371) for
children less than one year old, between one and ﬁve, and six
and older, respectively.
3.2. Time to CD4+ T-Lymphocyte Recovery. One hundred
and seventy-two (73.8%) of study subjects achieved im-
munological recovery, that is, achieved a target CD4+ T-
lymphocyte percentage of 25%, during the study period.
In the unadjusted analyses, the median recovery time for
all ages was 60weeks (95% CL: 55–65). Children between
ages one and ﬁve years recovered faster, with median
recovery time of 52weeks (95% CL: 38–60weeks), followed
by children less than one year old (median: 66weeks; 95%
CL: 19–210weeks), and then children six years or olderAIDS Research and Treatment 3
Table 1: Characteristics of 233 HIV-infected children on highly
active antiretroviral therapy (HAART) from 2004–2009, Accra,
Ghana.
Characteristics N (%)
Age category
<1year 10 (4.3)
1–5years 118 (51.0)
>6years 105 (45.1)
Gender
Female 112 (48.1)
Male 121 (51.9)
Immune recovery
No 61 (26.2)
Yes 172 (73.8)
WHO immune classiﬁcation
No evidence of suppression 31 (13.3)
Evidence of moderate suppression 80 (34.3)
Sever suppression 122 (52.4)
WHO clinical staging
I 33 (14.1)
II 53 (22.7)
III 106 (45.5)
IV 41 (17.6)
Previous TB diagnosis and treatment
Yes 119 (51.1)
No 114 (48.9)
Graduate of PMTCT program
Yes 3 (1.3)
No 203 (87.1)
Do not know 27 (11.6)
Mode of transmission
Vertical 199 (85.4)
Indeterminate 11 (4.7)
Do not know 23 (9.9)
Self report of adherence
Poor 13 (5.6)
Good 46 (19.8)
Excellent 144 (61.8)
Unknown 30 (12.9)
Parental HIV status
Both parents HIV-positive 28 (12.0)
Only one parent HIV-positive 128 (54.9)
Both parents unknown status 75 (32.2)
Mother unknown and father HIV-negative 2 (0.9)
Parental living status
Both parents alive 109 (46.8)
One parent known alive 79 (33.9)
Both parents dead 23 (9.9)
Both parents unknown 8 (3.4)
One parent alive and other unknown 14 (6.0)
(median: 69weeks; 95% CL: 57–84weeks). The median
r e c o v e r yt i m ew a ss h o r t e rf o rc h i l d r e nw i t hn oo rm o d e r a t e
evidence of immune suppression at the start of HAART
therapy and at least one parent alive (Table 2). We also
observed trends for the following predictors of faster CD4+
T-lymphocyte recovery: female gender (P = .06) and both
parents with HIV positive status (.10).
Kaplan-Meier curves of the cumulative probability over
time of CD4+ T-lymphocyte recovery stratiﬁed by age cate-
goryatstartofHAART,gender,WHOimmuneclassiﬁcation,
and parental living status are illustrated in Figure 1.
3.3. Predictors of Time to Recovery of CD4+ T-Lymphocyte.
In unadjusted analyses, starting HAART between 1–5 years
of age (HR = 1.64, P = .002), higher baseline CD4+ T-
lymphocyte count (HR = 1.05 per 100-cell increase, P =
.001), and having at least one parent alive (HR = 1.82,
P = .016) were signiﬁcantly associated with faster CD4+
T-lymphocyte recovery. We found a border line association
between female gender and time to recovery (HR = 1.34,
P = .059). There was no statistically signiﬁcant association
between mode of HIV transmission, parental HIV status,
WHO clinical staging, treatment adherence self-report, pre-
vious TB diagnosis and treatment, and CD4+ T-lymphocyte
recovery (Table 3).
Because baseline CD4+ T-lymphocyte was signiﬁcantly
associated with age at the start of HAART therapy and
since WHO immune classiﬁcation at the start of HAART
incorporates the eﬀect of child’s age, we retained WHO
immune classiﬁcation in the multivariate model instead
of baseline CD4+ T-lymphocytes. In a multivariate model
(Table 4), statistically signiﬁcant predictor variables of time
to recovery were parental living status (P = .025), gender
(P = .051), age at start of HAART (P = .014), and WHO
immune classiﬁcation at start of HAART (P<. 0001). The
probability of recovering faster was two times greater in
children with at least one parent alive than those with both
parents deceased (HR: 2.00, 95% CI: 1.18, 3.38). Females
were 1.37times more likely to achieve faster recovery than
males (HR: 1.37, 95% CI: 1.00, 1.87). Children who were
started on HAART between one and 5years of age had 1.59
times greater rate of recovery than children 6years of age or
older.
4.Discussion
Our ﬁndings corroborate with earlier, though few and
far in between, reports on the eﬃcacy of NNRTI-based
HAART regimens in HIV-infected children in resource-
limitedcountries.Moreover,weidentiﬁedpredictorvariables
that could be useful in developing a targeted approach to
CD4+ testing and cost-eﬀective monitoring of HAART with
CD4+ T-lymphocyte counts where resources are limited.
Furthermore, children with correlated variables predictive of
slow CD4+ T-lymphocyte recovery could be identiﬁed and
followed more frequently and carefully.
Seventy-four percent of study participants achieved
immunological recovery during the study followup period of
mean duration of 110 (SD = 67.7) weeks. The magnitude
of CD4+ T-lymphocyte recovery is consistent with other4 AIDS Research and Treatment
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Figure 1: Kaplan-Meier survival curves of CD4+ T-lymphocyte recovery versus signiﬁcant predictor variables of recovery for the 233HIV-
infected children on highly active antiretroviral therapy (HAART) from 2004 to 2009. (a) Age category: the median recovery time for ages
<12months, 1 to 6years, and ≥6years was 66, 52, and 69weeks, respectively (logrank, P = .004). (b) Gender: the median recovery time
for female and male was 58 and 67weeks, respectively (logrank, P = .056). (c) WHO immune classiﬁcation: the median recovery time for
no evidence of suppression, evidence of moderate suppression, and evidence of severe suppression was 52, 38, and 77weeks, respectively
(logrank, P = .004). (d) Parental living status: the median recovery time for at least one parent alive and both parents dead or “unknown”
was 59 and 75weeks, respectively (logrank, P = .014).
reports on pediatric antiretroviral therapy in resource-
limited countries [11, 12, 16, 22, 23]. In a study from Thai-
land with a median followup of 168weeks, the probability of
achievingCD4%ofgreaterorequalto25%rangedfrom65%
to 98% in children with baseline CD4% ranging from ≤5%
to24%[14].InareportoneﬃcacyofHAARTin14resource-
limited countries (including 10 from sub-Saharan Africa),
62% of children attained CD4 of ≥25% after one year of
receiving antiretroviral therapy [23]. In a cohort study from
Cambodia, median CD4% rose from 6% at baseline to
25% at 12months [16]. In contrast, the PATCG -219 study
reported that only 26% to 49% of children on HAART with
baseline CD4% ranging from <5 to 24% achieved CD4% >2
after three years on therapy [24, 25]. Moreover, the time
to CD4+ T-lymphocyte recovery in our cohort (the median
recovery was 60weeks) was shorter than most of the reports
from resource-rich countries but compared favorably with
that of studies from other resource-limited countries.
Although studies from sub-Saharan Africa have demon-
strated the eﬃcacy of HAART in HIV-infected children,
the predictors of immunological response have not been
investigated systematically [26]. In most centers, CD4+ T-
lymphocyte monitoring is either unavailable or done infre-
quently due to resource constraints. We found it expedient
for the same reasons to look at patient characteristics that
could predict immunological success in a resource-limited
setting. Statistically signiﬁcant predictor variables of CD4+
T-lymphocyte recovery in our study were age at startingAIDS Research and Treatment 5
Table 2: Median CD4+ T-lymphocyte recovery time among 233 HIV-infected children on highly active antiretroviral therapy (HAART)
from 2004–2009, Accra, Ghana.
Median recovery time, weeks (95% CL) P value of Log rank
Age category .004
<1year 66 (19, 210)
1–5years 52 (38, 60)
>6years 69 (57, 84)
WHO immune classiﬁcation <.0001
No evidence of suppression 52 (35, 56)
Evidence of moderate suppression 38 (32, 53)
Severe suppression 74 (63, 84)
Gender .056
Female 56 (44, 60)
Male 67 (56, 80)
Graduate of PMTCT <.0001
Yes 16 (2, 35)
No 60 (56, 66)
Parental living status .014
At least one parent alive∗ 59 (52, 62)
Both parents died or Do not know 75 (53, 150)
Parental HIV status
￿ .099
Both parents with HIV 39 (26, 60)
One parent with HIV 62 (57, 71)
∗Include those with “both parents alive”, “status known one alive”, and “status known one alive and another status unknown”.
￿N = 156. Exclude“both parents with unknown HIV status”(n = 75) and “mother unknown HIV status and father without HIV” (n = 2).
HAART, gender, WHO immune classiﬁcation, and parental
living status. WHO clinical staging, mode of transmission,
HIV status of parents, TB diagnosis and treatment, and
adherence to treatment regimen were not statistically signif-
icant predictors. Being a graduate of the Korle-Bu Teaching
HospitalPMTCTprogramwas asigniﬁcantpredictoroftime
to recovery; however, this ﬁnding was based on a very small
sample (N = 3). It is worth mentioning that the very few
numbers of HIV-infected children from the program attest
to the merit of the PMTCT programs. One can speculate
that the faster recovery rate ofgraduates of PMTCT program
who go on HAART may be due to good followup and strong
patient compliance.
Our ﬁnding that children aged 1–5 years at the start of
HAART achieve CD4+ T-lymphocyte recovery signiﬁcantly
faster than older children conﬁrms the results from previous
pediatric studies in both resource-limited and resource-rich
countries [14, 24, 27]. We also found that gender is an
indicator of faster CD4+ T-lymphocyte recovery, which is
consistent with a recent Thai study that reported female
children havinga betterimmunologicand virologicresponse
than males [14]. There are no reports from sub-Saharan
Africa on association between immune recovery and gender
in pediatrics, with the exception of one study that found
male gender to be associated with virologic failure [28].
T h er e a s o n sf o rt h i sg e n d e re ﬀect are not well understood.
Interestingly, in HIV-infected adults, gender diﬀerences in
treatment outcome (i.e., immunologic and virologic) have
received mixed reviews [29, 30].
Consistent with previous reports from resource-rich
settings [19, 31–33] and resource-limited countries [14, 28],
baseline absolute CD4+ T-lymphocyte count correlated pos-
itively with the rate of immune reconstitution. HIV-infected
children in the United States who began antiretroviral ther-
apy when severelyimmunosuppressed (CD4+ T-lymphocyte
<15%) had a signiﬁcantly shorter time to ﬁrst-line regimen
switch than children who were immunocompetent or mod-
erately immunosuppressed at initiation [34]. Combining the
eﬀect of age and baseline CD4+ T-lymphocyte on recovery
raises the importance of early diagnosis and treatment to
achieve immune reconstitution and preservation of ﬁrst-
line regimens. This is particularly pertinent to resource-
limited countries where second-line regimes are limited and
expensive.
Having at least one parent alive was found to predict
rate of immune recovery. This relationship may be rather
complex and there may be other contributing factors, con-
sidering the extended family structure and support in Africa.
Interestingly, a study from Cambodia found that children
who were orphaned were more likely to fail therapy, and the
authors attributed this to poor adherence to treatment [16].
Among childrenwith completeinformation onparental HIV
status (67%), having both HIV-positive parents contributed
to faster recovery than having one parent with HIV, albeit
statistically not signiﬁcant (P = .13). We are inclined to infer
that this is really a surrogate for having one versus both
parents alive, hence the stronger observed association of
parental living status with the outcome in our study.6 AIDS Research and Treatment
Table 3: Unadjusted associations of patient characteristics and time to CD4+ T-lymphocyte recovery among 233 HIV-infected children on
highly active antiretroviral therapy (HAART) from 2004–2009, Accra, Ghana.
N (%)§ Hazard Ratio P-value
Age category at ARV start .005
<1year 10 (4.3) 0.93 .864
1–5years 118 (51.0) 1.64 .002
>6years 105 (45.1) 1.00
preHAART CD4+ counts (per 102) 228 (97.9) 1.05 .001
WHO immune classiﬁcationat ARV start <.0001
No evidence of suppression 31 (13.3) 2.22 .0004
Evidence of moderate suppression 80 (34.3) 2.08 <.0001
Severe suppression 122 (52.4) 1.00
Gender .059
Female 112 (48.1) 1.34
Male 121 (51.9) 1.00
Mode of transmission .928
Vertical transmission 199 (85.4) 0.88 .715
Unknown 23 (9.9) 0.91 .842
Indeterminate¶ 11 (4.7) 1.00
Graduate of PMTCT program <.0001
Yes 3 (2.2) 4.77‡
No 201 (86.3) 1.00
Parental living status .054
Known both alive 109 (46.8) 1.80 .024
Known one alive 79 (33.9) 1.86 .020
Both died or unknown 31 (13.3) 1.00 —
Parental HIV status .241
Both parents with HIV 28 (12.0) 1.46 .131
One parents known with HIV 128 (54.9) 1.00 .999
Both parents unknown 75 (32.2) 1.00 —
WHO clinical staging at ARV start .197
I 32 (13.7) 0.98 .95
II 53 (22.7) 0.70 .98
III 106 (45.5) 1.09 .71
IV 41 (17.6) 1.00
Adherence self report .078
Poor 13 (5.6) 1.80 .131
Good 46 (19.8) 1.24 .607
Excellent 144 (61.8) 1.00
Unknown 30 (12.9)
Previous Tb diagnosis and treatment .803
Yes 119 (51.1) 0.15
No 114 (48.9) 1.00
§% corresponds to proportion of the 233subjects. The sum of % and N may not be up to 100% and 233, respectively, due to subjects with “unknown”
responses.
¶Subjects with history of possible maternal transmission, blood transfusion, or sexual abuse.
‡(95% CL: 2.90, 18.36).
CD4+ T-lymphocyte count is a signiﬁcant parameter
in monitoring ART in HIV-infected individuals [6, 35–
37]. In most resource-limited countries, treatment failure
is deﬁned by immunologic criteria due to the lack of
routine viral load monitoring. Unfortunately, not all HIV
centers have access to CD4+ T-lymphocyte monitoring due
to operational constraints. Despite that, recent studies in
children from resource-limited countries have demonstrated
that immunologic and virologic outcomes of antiretroviral
therapy is comparable to that of children in resource-rich
countries [11–18]. In these studies, on average the baseline
CD4+ T-lymphocyte count doubled after six months onAIDS Research and Treatment 7
Table 4: Adjusted associations of patient characteristics and time to CD4+ T-lymphocyte recovery in 233HIV-infected children on highly
active antiretroviral therapy (HAART) from 2004–2009, Accra, Ghana.
Predictors Hazard ratio (95% CL) P-value
Parental living status .025
Both parents alive 1.98 (1.18, 3.35)
One parent known to be alive 2.00 (1.18, 3.38)
Both parents dead or unknown 1.00
Gender .051
Female 1.37 (1.00, 1.87)
Male 1.00
Age category .014
<12months 0.98 (0.44, 2.20)
1–5years 1.59 (1.15, 2.19)
>6years 1.00
<12months∗ 0.62 (0.28, 1.37)
1–5 years 1.00
WHO immune classiﬁcation <.0001
No evidence of suppression 2.31 (1.48, 3.63)
Evidence of moderate suppression 2.04 (1.46, 2.86)
Severe suppression 1.00
∗Small sample size in children <12months.
therapy. The rate of increase remained the same over the
second 6 months and slowed thereafter. In one study, there
was no signiﬁcant increase in CD4+ T-lymphocyte count
at 12 and 24months [18]. This is consistent with studies
in HIV-infected adults where CD4+ T-lymphocyte recovery
plateaued after 4 to 5years of HAART despite complete
viral suppression [25, 33, 38]. From these studies, one can
s u r m i s et h a tf r e q u e n t( e . g . ,e v e r yt h r e et of o u rm o n t h s )
determination of CD4+ T-lymphocyte count may not be
necessary. Ourﬁndings of predictorsof CD4+T-lymphocyte
recovery further argue for the adoption of a more targeted
approach or “personalized” CD4+ T-lymphocyte testing,
particularly in resource-limited countries, rather than one
based on a general time interval. The testing interval could
bebased onan individual’spre-HAARTrisk ofhavinga poor
immune recovery rate.
Our study, like other retrospective studies, has inherent
limitationsandalso additionallimitationsduetooperational
constraints of resource-limited settings. It is a single center
study, and, therefore, one has to be cautious in generalizing
our ﬁndings. Moreover, data on viral loads were not
available, which precluded us from examining the eﬀect of
HAART on viral load and the correlation between viral
load and CD4+ T-lymphocytes. Our ﬁndings have to be
validated with eﬀect of HAART on viral load decline, since
it is not uncommon to have discordance in the gain of
CD4+T-lymphocytesanddeclineinviralload.Furthermore,
the data on adherence to therapy was by self-report and
not validated, so we did not use it in the ﬁnal model.
However, with these caveats, our ﬁndings are consistent with
previous studies, while our proposal of targeted approach to
CD4+ T-lymphocyte testing is worth further investigation
and validation.
5.Conclusion
Our study demonstrates that a clinically meaningful and
robust immune recovery in HIV-infected children on
HAART is attainable in resource-limited countries and that
there are patient characteristics that can predict time to
immune recovery. Based on these predictors, a followup
analysis can examine how well we can predict a time to
CD4+ T-lymphocyte recovery for an individual child so that
a targeted approach to CD4+ T-lymphocyte testing could be
adopted as a viable and potentially cost-eﬀective approach
in monitoring HAARTin HIV-infected children in resource-
limited countries.
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